US Patent Issued to ACTICOR BIOTECH, UNIVERSITE PARIS CITE, UNIVERSITE PARIS-XIII, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS-SACLAY on May 19 for "Inhibition of platelet aggregation using anti- human gpvi antibodies" (French Inventors)

ALEXANDRIA, Va., May 19 -- United States Patent no. 12,630,631, issued on May 19, was assigned to ACTICOR BIOTECH (Paris), UNIVERSITE PARIS CITE (Paris), UNIVERSITE PARIS-XIII (Villetaneuse, France), INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris Cedex, France) and UNIVERSITE PARIS-SACLAY (Gif-sur-Yvette, France).

"Inhibition of platelet aggregation using anti- human gpvi antibodies" was invented by Philippe Billiald (Paris), Martine Jandrot-Perrus (Vanves, France) and Gilles Avenard (Montrouge, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related con...